A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Condition:   Breast Cancer
Interventions:   Drug: Taselisib;   Drug: Placebo;   Drug: Fulvestrant
Sponsor:   Hoffmann-La Roche
Recruiting - verified May 2017

http://ift.tt/2rc1yMX